Material Name: Temazepam Soft Gelatin Capsules

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300

Material Name: Temazepam Soft Gelatin Capsules

Trade Name: Planum; Euhypnos
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as sedative-hypnotic

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Temazepam</td>
<td>846-50-4</td>
<td>212-688-1</td>
<td>10-20 mg***</td>
</tr>
<tr>
<td>Glycerol</td>
<td>56-81-5</td>
<td>200-289-5</td>
<td>*</td>
</tr>
<tr>
<td>Macrogol 300</td>
<td>Not assigned</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Anidrisorb 85/70</td>
<td>Not assigned</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>E 141 (colorant)</td>
<td>Not assigned</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>E 171 (colorant)</td>
<td>Not assigned</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Gelatin</td>
<td>9000-70-8</td>
<td>232-554-6</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary
*** per tablet/capsule/lozenge/suppository
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Capsules
Signal Word: WARNING

Statement of Hazard:
May be harmful if swallowed.
May cause central nervous system effects
May cause harm to the unborn child.
May cause harm to breastfed babies.

Additional Hazard Information:
Short Term: May be harmful if swallowed. (based on components).
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Use of this drug is habit forming. Addiction may occur.
Known Clinical Effects: The most common adverse effects seen during clinical use of this drug include drowsiness, lethargy, dizziness, confusion, anxiety, state of intense good feeling (euphoria), clumsy motion of limbs/trunk (ataxia), weakness, lightheadedness, incoordination. Cases of severe overdose may lead to coma, respiratory depression.

EU Indication of danger: Harmful
Toxic to reproduction, Category 2

EU Risk Phrases:
R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.

Skin Contact: Remove clothing and wash affected skin with soap and water. This material may not be completely removed by conventional laundering. Consult professional laundry service. Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Minimize dust generation and accumulation. Use with adequate ventilation.

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and flames.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Temazepam
Pfizer OEL TWA-8 Hr: 0.08 mg/m³

Glycerol
OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total
= 5 mg/m³ TWA
ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA
Australia TWA = 10 mg/m³ TWA

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.

Respiratory protection: Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Capsule
Molecular Formula: Mixture
Color: Yellow/orange
Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: None known
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers.

11. TOXICOLOGICAL INFORMATION

General Information: There are no data for this formulation. The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Temazepam
- Rat Oral LD50 1833 mg/kg
- Mouse Oral LD50 1963 mg/kg
- Rabbit Oral LD50 > 2400 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Glycerol
- Eye Irritation Rabbit Mild
- Skin Irritation Rabbit Mild

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Temazepam
- Peri-/Postnatal Development Rat Oral 60 mg/kg/day LOAEL Postnatal mortality
- Embryo / Fetal Development Rat Oral 30 mg/kg/day LOAEL Embryotoxicity
- Embryo / Fetal Development Rabbit Oral 40 mg/kg/day LOAEL Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Temazepam
- Direct DNA Damage Rat Hepatocyte Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Temazepam
- 18 Month(s) Mouse Oral 160 mg/kg/day NOAEL Not carcinogenic
- 2 Year(s) Rat Oral 160 mg/kg/day NOAEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Temazepam
- IARC: Group 3

Additional Information: Drugs of this class have caused adverse effect on breast feeding infants.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Harmful
Toxic to reproduction, Category 2

EU Risk Phrases:
R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.

EU Safety Phrases:
S22 - Do not breathe dust.
S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
WARNING
May be harmful if swallowed.
May cause central nervous system effects
May cause harm to the unborn child.
May cause harm to breastfed babies.

Canada - WHMIS: Classifications

WHMIS hazard class:
D2a  very toxic materials

Temazepam
California Proposition 65: developmental toxicity, initial date 4/1/90
Drug Enforcement Administration: Schedule IV
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
16. OTHER INFORMATION

Reasons for Revision:
Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.

Prepared by:
Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet